



OPEN ACCESS

APPROVED BY
Jaume Mora,
Sant Joan de Déu Hospital, Spain

*CORRESPONDENCE
Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 25 September 2023

ACCEPTED 25 September 2023

PUBLISHED 26 October 2023

CITATION

Frontiers Editorial Office (2023) Retraction:
Identification of hub genes and
construction of prognostic nomogram
for patients with Wilms tumors.
Front. Oncol. 13:1301668.
doi: 10.3389/fonc.2023.1301668

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: Identification of hub genes and construction of prognostic nomogram for patients with Wilms tumors

Frontiers Editorial Office*

A Retraction of the Original Research Article

Identification of hub genes and construction of prognostic nomogram for patients with Wilms tumors

by Lou L, Chen L, Wu Y, Zhang G, Qiu R, Su J, Zhao Z, Lu Z, Liao M and Deng X (2022) Identification of hub genes and construction of prognostic nomogram for patients with Wilms tumors. *Front. Oncol.* 12:982110. doi: 10.3389/fonc.2022.982110

The journal retracts the 21 October 2022 article cited above.

Following publication, concerns were raised regarding the use of the SK-NEP-1 cell line in the study to investigate Wilms' tumor. An investigation, which was conducted in accordance with Frontiers' policies, confirmed that the SK-NEP-1 cell line has been reclassified as belonging to the Ewing sarcoma family of tumors, rather than of Wilm's tumor origin.

It was found that the complaint was valid, and that the scientific validity of the article cannot be confirmed; therefore, the article has been retracted.

This retraction was approved by the Chief Editor of Frontiers in Oncology - Pediatric Oncology and the Chief Executive Editor of Frontiers. We thank the reader for raising this concern.